基于真实世界的丹参酮ⅡA磺酸钠注射液用于脑梗死治疗的用药特征分析  

Analysis on Medication Characteristics of Sodium TanshinoneⅡA Sulfonate Injection in Treatment of Cerebral Infarction Based on Real World

作　　者：张雷[1] 李青松[1] 黄豫[1] ZHANG Lei;LI Qingsong;HUANG Yu(Dept. of Pharmacy, Kunshan Hospital of Traditional Chinese Medicine, Jiangsu Kunshan 215300, China)

机构地区：[1]昆山市中医医院药剂科,江苏昆山215300

出　　处：《中国医院用药评价与分析》2020年第3期340-343,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：苏州市药学会-常州四药临床药学科研基金/苏州市2018年度科技发展计划(应用基础研究-医疗卫生)(No.SYSD2018223)。

摘　　要：目的:了解真实世界中丹参酮ⅡA磺酸钠注射液治疗脑梗死的临床应用特征,为规范临床用药提供参考。方法:基于昆山市中医医院信息系统,收集2016—2017年使用丹参酮ⅡA磺酸钠注射液治疗脑梗死的住院病例,共545例,对患者一般情况、临床用药特点及联合用药情况等进行统计分析。结果:545例使用丹参酮ⅡA磺酸钠注射液的脑梗死患者中,男性279例(占51.19%),女性266例(占48.81%),男女患者所占比例相近;平均年龄66.84岁,其中>45~80岁患者居多(409例,占75.05%);均采用静脉滴注给药,单次给药剂量以60 mg为主(463例,占84.95%);用药疗程多为1~14 d(508例,占93.21%),平均(7.15±4.71)d;与丹参酮ⅡA磺酸钠注射液联合应用的药品主要涉及奥美拉唑胶囊、前列地尔注射液、氢氯吡格雷片、阿托伐汀钙片、瑞舒伐汀钙片和硫辛酸注射液。结论:中老年人群是脑梗死发病的主要人群,临床使用丹参酮ⅡA磺酸钠注射液治疗时常与抗血小板聚集药、调节血脂药等联合应用,符合用药规范,但也存在超浓度用药等问题,应引起临床重视。OBJECTIVE:To investigate the characteristics of clinical application of sodium tanshinoneⅡA sulfonate injection in treatment of cerebral infarction in the real world,so as to provide references for standardizing clinical medication.METHODS:Based on the hospital information system in Kunshan Hospital of traditional Chinese Medicine,hospitalized cases of 545 patients with cerebral infarction who treated with sodium tanshinoneⅡA sulfonate injection from 2016 to 2017 were collected and analyzed in terms of patients’general information,medication characteristics and drug combination,etc.RESULTS:Of the 545 patients with cerebral infarction who treated with sodium tanshinoneⅡA sulfonate injection,279 cases were male(51.19%),266 were female(48.81%),with similar proportion;the average age was 66.84 years old,and most of patients were aged over 45 to 80 years old(409 cases,75.05%);all the patients were administered by intravenous drip,with the single dose was mainly 60 mg(463 cases,84.95%);the treatment course was mainly 1 to 14 days(508 cases,93.21%),with an average of(7.15±4.71)d;the drugs used in combination with sodium tanshinoneⅡA sulfonate injection mainly involving Omeprazole capsules,alprostadil injections,clopidogrel hydrogen tablets,Atorvastatin calcium tablets,Rosuvastatin calcium tablets and lipoic acid injection.CONCLUSIONS:The middle-aged and elderly people are the main population for the occurrence of cerebral infarction,the application of sodium tanshinoneⅡA sulfonate injection is often in combination with anti-platelet aggregation drugs and lipid-regulating drugs,although it conforms to the medication specifications,there are also problems such as over-concentration medications,which should be paid attention.

关 键 词：丹参酮ⅡA磺酸钠注射液 脑梗死 用药特征 联合用药 真实世界研究 

分 类 号：R972[医药卫生—药品]